Simmons H

Compass Pathfinder Ltd (a subsidiary of Compass Pathways plc), London, United Kingdom.

7 papers · 1 preprint

ArticlePsilocybin

The role of therapeutic alliance in psilocybin treatment for treatment-resistant depression: A post hoc path analysis.

Goodwin GM, Aaronson ST, Alvarez O +23

Europe PMC2026
PreprintMDMA

Assessing the suitability of ‘mass loss analysis’ as a low cost, low technology test to approximate MDMA content in ecstasy tablets, using laboratory and field comparisons

Pascoe M, Jones G, Simmons H +5

Europe PMC2025
ArticlePsilocybin

Corrigendum to "The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression" [Journal of Affective Disorders, Volume 372 (2025), Pages 523-532].

Goodwin GM, Aaronson ST, Alvarez O +28

Europe PMC2026
ArticlePsilocybin

Investigating the safety and tolerability of single-dose psilocybin for post-traumatic stress disorder: A nonrandomized open-label clinical trial.

McGowan NM, Rucker JJ, Yehuda R +6

Europe PMC2026
ArticlePsilocybin

The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression.

Goodwin GM, Aaronson ST, Alvarez O +28

Europe PMC2025
ArticlePsilocybin

The impact of antidepressant discontinuation prior to treatment with psilocybin for treatment-resistant depression.

Marwood L, Croal M, Mistry S +4

Europe PMC2024
ArticlePsilocybin

Improvement in Depression Symptoms Measured by Montgomery-Åsberg Depression Rating Scale and Quick Inventory of Depressive Symptomatology-Self Rated Items after Randomised Double-blind COMP360 Psilocybin Therapy for Treatment-resistant Depression

Goodwin G, Marwood L, Mistry S +6

Europe PMC2023
ArticlePsilocybin

Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication.

Goodwin GM, Croal M, Feifel D +11

Europe PMC2023